A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies

• Main Authors: Ho, Jingshan, Heong, Valerie, Yong, Wei Peng, Soo, Ross, Chee, Cheng Ean, Wong, Andrea, Sundar, Raghav, Thian, Yee Liang, Gopinathan, Anil, Pang, Mei Yan, Koe, Priscillia, Jeraj, Santhiay Nathan, Soe, Phyu Pyar, Soe, Mu Yar, Tang, Tiffany, Ng, Matthew CH, Tai, David WM, Tan, Tira JY, Xu, Hongmei, Chang, Hua, Landesman, Yosef, Shah, Jatin, Shacham, Sharon, Lee, Soo Chin, Tan, Daniel SW, Goh, Boon Cher, Tan, David SP
• Other Authors: CANCER SCIENCE INSTITUTE OF SINGAPORE
• Format: Article
• Language: English
• Published: SAGE PUBLICATIONS LTD 2022
• Subjects: Science & Technology; Life Sciences & Biomedicine; Oncology; advanced malignancies; Asian; clinical trial; phase 1; selinexor; ANTITUMOR-ACTIVITY; DEXAMETHASONE; 1ST-IN-CLASS; CONSENSUS; LYMPHOMA; CRITERIA
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/226297
• Institution: National University of Singapore

10.1177/17588359221087555